Acceleron to Present at Two Upcoming Healthcare Investor Conferences
13 Febrero 2019 - 6:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics intended to treat serious and rare diseases, today
announced that senior management will present at two upcoming
healthcare investor conferences.
Conference Presentation
Details:
Event: SVB Leerink 8th Annual Global Healthcare
ConferenceDate/Time: Thursday, February 28, 2019 at 3:00
p.m. ETLocation: New York, NY
Event: Cowen & Co. 39th Annual Healthcare
ConferenceDate/Time: Monday, March 11, 2019 at 1:30 p.m.
ETLocation: Boston, MA
A live webcast for the SVB Leerink and Cowen & Co.
conference presentations may be accessed on the Investors/Media
page of the Company's website at www.acceleronpharma.com. A replay
of each webcast will be available approximately two hours after the
event on the Acceleron website.
About Acceleron
Acceleron is a clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company's
leadership in the understanding of TGF-beta biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2
pulmonary program with sotatercept in pulmonary arterial
hypertension.
For more information, please
visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190213005109/en/
Acceleron Pharma Inc.Investors:Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate Communications
Media:Matt Fearer, 617-301-9557Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024